Barclays initiated coverage of Senseonics (SENS) with an Overweight rating and $1.50 price target The firm says the company’s Eversense 365 implantable continuous glucose monitoring sensor system creates a “new and important category” within the market for people with diabetes who suffer fatigue. Barclays expects the 365 to drive a significant lift in demand in the second half of 2026 and 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SENS:
- Senseonics (SENS) Earnings Call Highlights Growth and Future Plans
- Senseonics Holdings: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Senseonics Holdings Reports Strong Q2 Revenue Growth
- Senseonics reports Q2 EPS (2c), consensus (2c)
- Senseonics backs FY25 revenue view to $34M-$38M, consensus $35.9M